Navigation Links
KemPharm, Inc. Receives Notice of Issuance From USPTO on Patent Protecting Company's ADHD Prodrug Technology
Date:8/16/2010

NORTH LIBERTY, Iowa, Aug. 16 /PRNewswire/ -- KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same", U.S. Patent No. 7,772,222.  This patent protects broad aspects of the Company's core Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.  The patent includes key related compounds to the Company's lead clinical candidate KP106, a new chemical entity (NCE) composed of the active pharmaceutical compound d-amphetamine and a ligand, which recently successfully completed a Phase 1 clinical trial.  

(Logo: http://photos.prnewswire.com/prnh/20100518/CG06271LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100518/CG06271LOGO)

"This Notice of Issuance signals a major accomplishment for KemPharm as it marks the first issued patent protecting compounds related to KP106 and other ADHD drugs derived from our LAT platform," stated Travis Mickle, Ph.D., President & CSO for KemPharm.  "Obtaining this patent within four years of founding KemPharm validates our efficient approach to securing intellectual property and highlights the value of our proprietary LAT technology.  This is the first of what we anticipate to be many patents we expect to have issued that protect our products under development covering various CNS indications."  

"Intellectual property is an important strategic focus for a prodrug company like KemPharm," added Sven Guenther, Ph.D., Vice President of Research.  "Since most of our programs are designed to improve already marketed drugs, we pay particular attention to how we can differentiate our products from potential prior art before we ever synthesize a molecule utilizing LAT.  We are pleased that the USPTO has acknowledged the novel aspects and non-obvious results generated by our ADHD portfolio and granted protection of our discoveries."

About KP106KP106, KemPharm's lead prodrug candidate for the treatment of ADHD, is composed of d-amphetamine and a ligand.  In preclinical studies, KP106 demonstrated unique abuse deterrent properties along with pharmacokinetics indicative of an attenuated amphetamine exposure as compared to Vyvanse®.  These data predict that patients receiving KP106 may experience decreased side effects and decreased risk of abuse typically associated with stimulants.  Importantly, KemPharm is positioning KP106 to be the first ever proprietary thin film dosage form for ADHD to address compliance issues, in particular, for the pediatric patient population.  KemPharm projects the filing of a new drug application (NDA) for KP106 by the end of 2012.

About KemPharm, Inc.KemPharm, Inc. is focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable LAT prodrug approach.  KemPharm utilizes its LAT prodrug technology to generate improved versions of FDA-approved drugs.  Each NCE creates new composition-based intellectual property, may have a shorter development timeline and reduced development costs, and may be eligible for 505(b)(2) regulatory submission.  The Company's business strategy includes seeking strategic development partners following rapid clinical proof of concept demonstration in a Phase 1 trial.  KemPharm also plans to explore discovery stage alliances with industry leaders, leveraging its prodrug know-how and LAT technology platform.  KemPharm is developing candidates for ADHD, pain, other central nervous system disorders, cardiovascular disease and cancer.  www.kempharm.com

Forward Looking Statements and InformationThis release contains forward-looking statements which are not based upon historical fact, including, without limitation, "will," "should," "expect," "anticipate," "plan," "predict," "believe," "may" and "project."  Such statements, including statements relating to developments, progress, timelines, plans of our clinical and preclinical programs, and potential benefits of KemPharm Inc.'s product candidates, involve various assumptions, known and unknown risks, and uncertainties which may cause actual results or events to be materially different and adverse from those expressed in or implied by the forward-looking statements.  Such assumptions, risks and uncertainties may relate to difficulties or delays in discovery, development, testing, and regulatory approval of the company's product candidates, results that are inconsistent with preclinical results, unexpected adverse side effects, or inadequate therapeutic efficacy of the product candidates.  The forward-looking statements in this release speak only as of this date, and KemPharm disclaims any obligation to update publicly any forward-looking statement to reflect the occurrence of events or circumstances after the date hereof.Contacts:KemPharm, Inc.Kate Holt, Ph.D. 319-665-2575E-mail: info@kempharm.com
'/>"/>

SOURCE KemPharm, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PDL BioPharma Receives Letter from Genentech Relating to European Patents
2. Sigma-Aldrich® Receives National Institutes of Health Funding for Cardiovascular Disease Research
3. PolyGel® Receives SADMERC Approval for L-Code L3670 for ThermoActive™ Cold & Hot Mobile Compression Shoulder Orthosis
4. Accurays CyberKnife® G4 System Receives Shonin Approval
5. AdvanDx Receives FDA 510(k) Clearance for 90 Minutes Protocol for Yeast Traffic Light® PNA FISH®
6. Abbotts SIMCOR ® ( niacin extended-release / simvastatin ) Receives FDA Approval for New Dosage Strengths
7. Instrumentation Laboratory Receives FDA Clearance for New Automated Total Bilirubin Assay on GEM Premier 4000 Critical Care Analyzer
8. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
9. Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
10. CardioGenics Holdings Inc. Receives New Ticker Symbol
11. Actavis Receives Approval of Bupropion HCl SR 100mg and 200mg in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):